The story of Sildenafil presents a intricate picture for shareholders. While the initial introduction generated significant returns, the lapse of its intellectual property protection opened the floodgates to cheaper https://getsocialsource.com/story7126103/the-copyright-and-the-pharmaceutical-industry-a-risky-bet